Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Non-Current Assets: 2010-2025

Historic Non-Current Assets for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Sep 2025 value amounting to $199.1 million.

  • Catalyst Pharmaceuticals' Non-Current Assets fell 14.53% to $199.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $199.1 million, marking a year-over-year decrease of 14.53%. This contributed to the annual value of $227.8 million for FY2024, which is 9.16% down from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Non-Current Assets of $199.1 million as of Q3 2025, which was down 6.58% from $213.2 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Non-Current Assets high stood at $250.8 million for Q4 2023, and its period low was $24.8 million during Q2 2022.
  • For the 3-year period, Catalyst Pharmaceuticals' Non-Current Assets averaged around $223.0 million, with its median value being $223.2 million (2025).
  • In the last 5 years, Catalyst Pharmaceuticals' Non-Current Assets skyrocketed by 13,129.86% in 2021 and then dropped by 27.75% in 2022.
  • Over the past 5 years, Catalyst Pharmaceuticals' Non-Current Assets (Quarterly) stood at $27.7 million in 2021, then soared by 98.05% to $54.8 million in 2022, then surged by 357.44% to $250.8 million in 2023, then declined by 9.16% to $227.8 million in 2024, then declined by 14.53% to $199.1 million in 2025.
  • Its Non-Current Assets was $199.1 million in Q3 2025, compared to $213.2 million in Q2 2025 and $223.2 million in Q1 2025.